{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytidine", "query": { "intervention": "cytidine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 3780, "total_pages": 378, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytidine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T17:32:16.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00523640", "title": "A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "combination of gemcitabine, capecitabine, and bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-03", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00523640" }, { "nct_id": "NCT01967940", "title": "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "Current failing ARV regimen", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-10-25", "completion_date": "2017-07-31", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 5, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Wilton Manors", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967940" }, { "nct_id": "NCT00004097", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004097" }, { "nct_id": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Recurrent Myelodysplastic Syndrome", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "Navitoclax", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-01-12", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564650" }, { "nct_id": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults", "AML (Adult) With 11q23 (MLL) Abnormalities", "AML (Adult) With Del (5q)", "AML (Adult) With Inv (16) (p13; q22)", "AML (Adult) With t (16;16) (p13; q22)", "AML (Adult) With t (8; 21) (q22; q22)", "Secondary AML (Adult)", "Untreated AML (Adult)" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Midostaurin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Iberri", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 13, "start_date": "2013-06", "completion_date": "2016-08-31", "has_results": true, "last_update_posted_date": "2018-09-27", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846624" }, { "nct_id": "NCT02210559", "title": "A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer (Unresectable)" ], "interventions": [ { "name": "FG-3019", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-07-31", "completion_date": "2021-12-15", "has_results": true, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02210559" }, { "nct_id": "NCT00384839", "title": "Vidaza to Restore Hormone Thx Prostate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "azacitidine for injectable suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2006-04", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2018-10-25", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 13, "location_summary": "Denver, Colorado • Ocoee, Florida • Minneapolis, Minnesota + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384839" }, { "nct_id": "NCT01600807", "title": "OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer, Metastatic" ], "interventions": [ { "name": "Gemcitabine, Erlotinib, OSI-906", "type": "DRUG" }, { "name": "Gemcitabine, Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01600807" }, { "nct_id": "NCT00000916", "title": "A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 399, "start_date": null, "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Mateo", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000916" }, { "nct_id": "NCT00047047", "title": "Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "tanespimycin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2002-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-09-11T17:32:16.300Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047047" } ] }